AstraZeneca: Beyfortus approved in Japan
Beyfortus is expected to be available for the upcoming RSV 2024/25 season, in line with existing Japanese guidelines.
The Japanese Ministry of Health, Labor and Welfare's approval is based on three late-stage pivotal clinical trials of Beyfortus, which showed that a single dose of Beyfortus demonstrated consistent efficacy against RSV LRTD extending over five months, the duration of a typical RSV season.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction